Prognosis of Classical Hodgkin Lymphoma in Adolescents

Introduction to Prognostic Factors

The prognosis for an adolescent with classical Hodgkin lymphoma is excellent, with permanent remission rates of 80-90% and overall 5-year survival exceeding 90% with modern therapeutic strategies 1

The prognosis mainly depends on the disease stage and the presence of risk factors at diagnosis, including a bulky mediastinal mass, which is a major risk factor 2
Chest radiography and tomodensitometry of the neck, chest, and abdomen are mandatory to identify a bulky mediastinal mass (>1/3 of the maximum horizontal thoracic diameter) 2
PET scan should be considered according to the revised response criteria for accurate staging 2
Bone marrow biopsy with aspiration and histology is mandatory 2
Complete biological assessment including blood cell count, erythrocyte sedimentation rate (ESR), alkaline phosphatase, LDH, liver enzymes, albumin, and TSH is required 2

Patients are classified according to the Ann Arbor system into three categories 2
For patients with limited stage (I-II without risk factors), the 5-year disease-free survival is not explicitly stated in the provided citations, however, the overall strategy for their treatment is based on the Ann Arbor staging system 2

For limited stage, four cycles of ABVD followed by 30 Gy of involved-field radiotherapy represent the standard treatment, with complete remission rates of 100% in recent studies 3
For intermediate stage, four cycles of ABVD followed by 30 Gy of radiotherapy are widely considered standard 3
For advanced stage, six to eight cycles of ABVD or eight cycles of escalated BEACOPP followed by localized radiotherapy of 30 Gy on residual lymphomatous masses >1.5 cm 3, 4

Reproductive counseling should be offered before treatment because chemotherapy and radiotherapy can cause permanent damage to fertility 2
Mandatory pre-treatment evaluation includes tests of cardiac and pulmonary function to identify patients at increased risk of acute and/or long-term complications 2
Mandatory screening for hepatitis B, hepatitis C, and HIV is required 2

Bulky mediastinal mass is a significant unfavorable prognostic factor 2, 6
Extranodal disease, high ESR, ≥3-4 involved nodal sites, and B symptoms (fever, night sweats, weight loss) are also unfavorable prognostic factors 2

Intermediate PET scan after 2-4 cycles of chemotherapy is a good predictor of treatment failure in patients with advanced Hodgkin lymphoma treated with ABVD, although therapeutic stratification based on intermediate PET scan cannot yet be considered standard 3, 7, 1

If relapse occurs, high-dose chemotherapy followed by autologous stem cell transplantation can be considered the treatment of choice, with acceptable remission rates 7, 4, 1